journal article·2025-08

Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum

Ling-Li Wang, Ming-Hua Zheng, Jing-Yi Jin, Shoujun Zhu, Songling Zhang

Science China Materials· Volume 68· Issue 8
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Adenosine and Purinergic Signaling · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. Klein IA, Boija A, Afeyan LK, et al. Partitioning of cancer therapeutics in nuclear condensates. Science, 2020, 368: 1386–139210.1126/science.aaz4427 ↗
2. Howard TP, Roberts CWM. Partitioning of chemotherapeutics into nuclear condensates—opening the door to new approaches for drug development. Mol Cell, 2020, 79: 544–54510.1016/j.molcel.2020.07.029 ↗
3. Saminathan A, Zajac M, Anees P, et al. Organelle-level precision with next-generation targeting technologies. Nat Rev Mater, 2022, 7: 355–37110.1038/s41578-021-00396-8 ↗
4. Zielonka J, Joseph J, Sikora A, et al. Mitochondria-targeted triphenyl-phosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev, 2017, 117: 10043–1012010.1021/acs.chemrev.7b00042 ↗
5. Peng X, Tang S, Tang D, et al. Autonomous metal-organic framework nanorobots for active mitochondria-targeted cancer therapy. Sci Adv, 2023, 9: eadh173610.1126/sciadv.adh1736 ↗
6. Wang W, Zhang Y, Wang Z, et al. A native drug-free macromolecular therapeutic to trigger mutual reinforcing of endoplasmic reticulum stress and mitochondrial dysfunction for cancer treatment. ACS Nano, 2023, 17: 11023–1103810.1021/acsnano.3c03450 ↗
7. Liu C, Li L, Lyu J, et al. Split bullets loaded nanoparticles for amplified immunotherapy. J Control Release, 2022, 347: 199–21010.1016/j.jconrel.2022.05.011 ↗
8. Zhen W, An S, Wang S, et al. Precise subcellular organelle targeting for boosting endogenous-stimuli-mediated tumor therapy. Adv Mater, 2021, 33: 21057210.1002/adma.202101572 ↗
9. Zhou Q, Xiang J, Qiu N, et al. Tumor abnormality-oriented nanomedicine design. Chem Rev, 2023, 123: 10920–1098910.1021/acs.chemrev.3c00062 ↗
10. Sharma A, Verwilst P, Li M, et al. Theranostic fluorescent probes. Chem Rev, 2024, 124: 2699–280410.1021/acs.chemrev.3c00778 ↗
11. Zhao J, Li X, Ma T, et al. Glutathione-triggered prodrugs: design strategies, potential applications, and perspectives. Med Res Rev, 2024, 44: 1013–105410.1002/med.22007 ↗
12. Zhang H, Liu T, Sun Y, et al. Carbon-spaced tandem-disulfide bond bridge design addresses limitations of homodimer prodrug nanoassemblies: enhancing both stability and activatability. J Am Chem Soc, 2024, 146: 22675–2268810.1021/jacs.4c07312 ↗
13. Shi L, Lin S, Zhou F, et al. Recent advances in engineering prodrug-based nanomedicines for cancer therapy. Mater Adv, 2024, 5: 4634–465910.1039/D3MA01132A ↗
14. Luo X, Gong X, Su L, et al. Activatable mitochondria-targeting organoarsenic prodrugs for bioenergetic cancer therapy. Angew Chem Int Ed, 2021, 60: 1403–141010.1002/anie.202012237 ↗
15. Jangili P, Kong N, Kim JH, et al. DNA-damage-response-targeting mitochondria-activated multifunctional prodrug strategy for self-defensive tumor therapy. Angew Chem Int Ed, 2022, 61: e20211707510.1002/anie.202117075 ↗
16. Zhuang J, Li N, Zhang Y, et al. Esterase-activated theranostic prodrug for dual organelles-targeted imaging and synergetic chemo-photodynamic cancer therapy. CCS Chem, 2022, 4: 1028–104310.31635/ccschem.021.202100985 ↗
17. Tian M, Zhan J, Lin W. Single fluorescent probes enabling simultaneous visualization of duple organelles: design principles, mechanisms, and applications. Coord Chem Rev, 2022, 451: 21426610.1016/j.ccr.2021.214266 ↗
18. Wang LL, Mai YZ, Zheng MH, et al. A single fluorescent probe to examine the dynamics of mitochondria-lysosome interplay and extracellular vesicle role in ferroptosis. Dev Cell, 2024, 59: 517–528.e310.1016/j.devcel.2024.01.003 ↗
19. Wang LL, Zhang YR, Zheng MH, et al. A single fluorescent probe reveals changes in endoplasmic reticulum-mitochondria contact in hepatocytes during ferroptosis. Chem Eng J, 2023, 466: 14310410.1016/j.cej.2023.143104 ↗
20. Wang LL, Xu Q, Xie YZ, et al. A triple-targeting fluorescent probe reveals the glutathione and viscosity crosstalk in mitochondria, endoplasmic reticulum, and nucleoli in cells during ferroptosis. Sens Actuat B-Chem, 2024, 399: 13487210.1016/j.snb.2023.134872 ↗
21. Tang Z, Liu Y, He M, et al. Chemodynamic therapy: tumour microenvironment-mediated fenton and fenton-like reactions. Angew Chem Int Ed, 2019, 58: 946–95610.1002/anie.201805664 ↗
22. Gao S, Han Y, Fan M, et al. Metal-organic framework-based nanocatalytic medicine for chemodynamic therapy. Sci China Mater, 2020, 63: 2429–243410.1007/s40843-020-1513-8 ↗
23. Lu Y, Zhang P, Zhou Y, et al. Novel nanocarrier for promoting tumor synergistic therapy by down-regulation of heat shock proteins and increased Fe3+ supply. Sci China Chem, 2023, 66: 1078–108510.1007/s11426-022-1505-8 ↗
24. Zhao P, Li H, Bu W. A forward vision for chemodynamic therapy: issues and opportunities. Angew Chem Int Ed, 2023, 62: e20221041510.1002/anie.202210415 ↗
25. Ge D, Ren D, Duan Y, et al. Hollow MnO2-based multifunctional nanoplatform for enhanced tumor chemodynamic therapy. Sci China Mater, 2025, 68: 292–30210.1007/s40843-024-3177-5 ↗
26. Mai YZ, Xie YZ, Zheng MH, et al. Facile synthesis of pyronin-9-thione via a trisulfur radical anion mechanism. New J Chem, 2021, 45: 19–2210.1039/D0NJ04808A ↗
27. Chen Z, Li Q, Wang X, et al. Potent method for the simultaneous determination of glutathione and hydrogen peroxide in mitochondrial compartments of apoptotic cells with microchip electrophoresis-laser induced fluorescence. Anal Chem, 2010, 82: 2006–201210.1021/ac902741r ↗
28. Li L, Wang X, Li Q, et al. An accurate mass spectrometric approach for the simultaneous comparison of GSH, Cys, and Hcy in L02 cells and HepG2 cells using new NPSP isotope probes. Chem Commun, 2015, 51: 11317–1132010.1039/C5CC03157E ↗
29. Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ, 2016, 23: 369–37910.1038/cdd.2015.158 ↗
30. Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc, 2014, 136: 4551–455610.1021/ja411006a ↗
31. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012, 149: 1060–107210.1016/j.cell.2012.03.042 ↗
32. Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell, 2022, 185: 2401–242110.1016/j.cell.2022.06.003 ↗
33. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol, 2001, 107: 751–76210.1067/mai.2001.114239 ↗
34. Reynolds JL, Akhter J, Morris DL. In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. Melanoma Res, 1996, 6: 95–10010.1097/00008390-199604000-00003 ↗
35. Chen S, Luster AD. Antihistamines for cancer immunotherapy: more than just treating allergies. Cancer Cell, 2022, 40: 9–1110.1016/j.ccell.2021.11.007 ↗
36. Inoue-Yamauchi A, Jeng PS, Kim K, et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun, 2017, 8: 1607810.1038/ncomms16078 ↗
37. Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol, 2024, 25: 379–39510.1038/s41580-023-00689-6 ↗
38. Glover HL, Schreiner A, Dewson G, et al. Mitochondria and cell death. Nat Cell Biol, 2024, 26: 1434–144610.1038/s41556-024-01429-4 ↗
39. Zhang JX, Yuan WC, Li CG, et al. A review on the mechanisms underlying the antitumor effects of natural products by targeting the endoplasmic reticulum stress apoptosis pathway. Front Pharmacol, 2023, 14: 129313010.3389/fphar.2023.1293130 ↗
40. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol, 2021, 22: 266–28210.1038/s41580-020-00324-8 ↗
41. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 2003, 3: 401–41010.1038/nrc1093 ↗
42. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell, 2012, 148: 1145–115910.1016/j.cell.2012.02.035 ↗
43. Scheid AD, Beadnell TC, Welch DR. Roles of mitochondria in the hallmarks of metastasis. Br J Cancer, 2021, 124: 124–13510.1038/s41416-020-01125-8 ↗